{"id":48478,"date":"2025-11-17T19:58:39","date_gmt":"2025-11-17T11:58:39","guid":{"rendered":"https:\/\/flcube.com\/?p=48478"},"modified":"2025-11-17T19:58:40","modified_gmt":"2025-11-17T11:58:40","slug":"akeso-secures-nmpa-approval-for-ak152-first-bispecific-antibody-targeting-alzheimers-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48478","title":{"rendered":"Akeso Secures NMPA Approval for AK152 \u2013 First Bispecific Antibody Targeting Alzheimer\u2019s in China"},"content":{"rendered":"\n

Akeso Inc.<\/strong> (HKG: 9926<\/a>) announced that its self\u2011developed bispecific antibody AK152<\/strong> has received regulatory approval from the National Medical Products Administration (NMPA)<\/strong> to launch clinical trials in patients with Alzheimer\u2019s disease (AD)<\/strong>.<\/p>\n\n\n\n

Product & Mechanism<\/h2>\n\n\n\n
Feature<\/th>Detail<\/th><\/tr><\/thead>
Type<\/strong><\/td>Bispecific antibody<\/td><\/tr>
Targets<\/strong><\/td>Amyloid\u2011\u03b2 (A\u03b2) and high\u2011expression receptors on the blood\u2011brain barrier (BBB)<\/strong><\/td><\/tr>
Novelty<\/strong><\/td>First bispecific AD drug approved in China for disease\u2011modifying therapy<\/td><\/tr>
Preclinical Efficacy<\/strong><\/td>Rapid A\u03b2 plaque clearance; ~3\u2011fold higher brain penetration vs. traditional monoclonal antibodies<\/td><\/tr>
Safety Profile<\/strong><\/td>Favorable; no off\u2011target toxicities observed in vitro<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

AK152\u2019s dual\u2011binding design couples a classic anti\u2011A\u03b2 arm with an affinity module for BBB\u2011relevant receptors, thereby facilitating transport across the BBB<\/strong>. Compared with conventional monoclonal antibodies, the bispecific format increases cerebral delivery, hastens plaque removal, and shows \u201csignificantly superior therapeutic efficacy\u201d in animal models.<\/p>\n\n\n\n

Preclinical Highlights<\/h2>\n\n\n\n